ROIV

+ Watchlist + Portfolio

Roivant Sciences Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $37.40
52-Week Range: $11.54 – $37.97
Market Cap: $26.61B
P/E (TTM): —
EPS (TTM): -0.47
Dividend Yield: —

Advanced Metrics

Price/Book: 5.86
PEG Ratio: —
Return on Equity: -8.52%
Return on Assets: -16.48%
Gross Margin: 0.00%
Operating Margin: -25408.11%
Profit Margin: 0.00%
Current Ratio: 16.72
Debt/Equity: 0.02
Total Debt: $107.15M
Free Cash Flow: $-1.13B
Revenue Growth: -33.50%
Earnings Growth: —
Enterprise Value: $23.97B

ROIV Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Revenue	$31.53M	$32.71M	$29.05M	$8.26M
Cost of Revenue	$3.03M	$1.60M	$911.00K	$1.28M
Gross Profit	$28.50M	$31.11M	$28.14M	$6.97M
Research & Development	$454.06M	$439.91M	$550.41M	$681.81M
Selling, General & Admin	$383.45M	$416.13M	$591.41M	$610.47M
Operating Expenses	$837.51M	$856.04M	$1.14B	$1.29B
Operating Income	-$809.01M	-$824.93M	-$1.11B	-$1.29B
EBITDA	-$790.16M	-$802.89M	-$1.10B	-$1.28B
Pretax Income	-$884.99M	$4.57B	-$681.59M	-$264.58M
Income Tax	$4.08M	$21.50M	$48.17M	$133.33M
Net Income	-$1.01B	$4.35B	-$171.98M	-$299.77M
Diluted EPS	-1.42	5.23	-0.24	-0.54
Diluted Shares	712.79M	831.05M	725.40M	693.86M

ROIV Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$1.68B	$6.49B	$2.72B	$1.42B
Receivables	$37.64M	$82.81M	$0.00	$770.24M
Inventory	$2.76M	$35.25M	—	—
Current Assets	$1.80B	$6.73B	$5.00B	$5.17B
Total Assets	$2.39B	$7.22B	$5.44B	$5.71B
Current Liabilities	$272.45M	$266.76M	$149.41M	$281.24M
Long-Term Debt	$375.51M	$430.59M	—	—
Total Debt	$481.40M	$53.99M	$100.17M	$107.44M
Total Liabilities	$782.02M	$773.95M	$249.74M	$416.27M
Retained Earnings	-$3.77B	$576.17M	$116.06M	-$501.81M
Shareholders' Equity	$1.16B	$5.97B	$4.69B	$4.53B
Working Capital	$1.53B	$6.47B	$4.85B	$4.89B

ROIV Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$843.39M	-$765.27M	-$839.45M	-$750.35M
Capital Expenditure	-$12.69M	-$1.38M	-$4.60M	-$8.21M
Free Cash Flow	-$856.08M	-$766.65M	-$844.05M	-$758.56M
Depreciation & Amortisation	$18.86M	$22.04M	$14.07M	$3.35M
Stock-Based Compensation	$217.78M	$199.63M	$289.03M	$346.17M
Investing Cash Flow	-$44.27M	$5.20B	-$1.77B	-$682.33M
Financing Cash Flow	$499.46M	$419.36M	-$1.22B	$134.24M
Share Repurchases	$0.00	$0.00	-$1.29B	-$319.50M
Net Change in Cash	-$388.20M	$4.86B	-$3.83B	-$1.30B

ROIV Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$7.57M	$2.17M	$1.57M	$2.00M	$2.52M
Cost of Revenue	$205.00K	$154.00K	$111.00K	$700.00K	$320.00K
Gross Profit	$7.37M	$2.02M	$1.46M	$1.30M	$2.20M
Research & Development	$145.24M	$152.92M	$164.57M	$165.38M	$198.94M
Selling, General & Admin	$147.09M	$134.02M	$143.13M	$175.07M	$158.25M
Operating Expenses	$292.33M	$286.94M	$307.69M	$340.45M	$357.19M
Operating Income	-$284.96M	-$284.92M	-$306.23M	-$339.15M	-$355.00M
EBITDA	-$283.54M	-$283.82M	-$305.31M	-$338.46M	-$354.36M
Pretax Income	-$203.05M	-$269.26M	-$159.04M	-$290.37M	$454.10M
Income Tax	$49.32M	$4.65M	$7.00M	$23.33M	$98.35M
Net Income	-$206.47M	-$223.35M	-$113.52M	-$265.89M	$302.99M
Diluted EPS	-0.29	-0.33	-0.17	-0.38	0.28
Diluted Shares	707.30M	680.29M	680.95M	696.86M	812.29M

ROIV Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$2.72B	$1.24B	$1.24B	$1.48B	$1.42B
Receivables	$0.00	—	—	—	$770.24M
Current Assets	$5.00B	$4.62B	$4.51B	$4.66B	$5.17B
Total Assets	$5.44B	$5.03B	$5.06B	$5.23B	$5.71B
Current Liabilities	$149.41M	$113.87M	$133.86M	$151.96M	$281.24M
Total Debt	$100.17M	$99.69M	$98.85M	$108.94M	$107.44M
Total Liabilities	$249.74M	$216.70M	$257.14M	$251.14M	$416.27M
Retained Earnings	$116.06M	-$315.59M	-$429.11M	-$695.00M	-$501.81M
Shareholders' Equity	$4.69B	$4.35B	$4.36B	$4.27B	$4.53B
Working Capital	$4.85B	$4.50B	$4.38B	$4.51B	$4.89B

ROIV Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$172.56M	-$204.38M	-$185.66M	-$196.48M	-$163.82M
Capital Expenditure	-$811.00K	-$4.04M	-$7.85M	—	-$1.26M
Free Cash Flow	-$173.38M	-$208.42M	-$193.51M	-$191.55M	-$165.08M
Depreciation & Amortisation	$1.43M	$1.10M	$921.00K	$691.00K	$638.00K
Stock-Based Compensation	$83.49M	$82.18M	$81.82M	$105.00M	$77.17M
Investing Cash Flow	$1.07B	-$1.09B	$120.42M	$109.47M	$173.49M
Financing Cash Flow	-$177.15M	-$187.77M	$62.59M	$328.19M	-$68.78M
Share Repurchases	-$295.44M	-$208.29M	$0.00	$0.00	-$111.21M
Net Change in Cash	$724.48M	-$1.48B	-$2.65M	$241.18M	-$59.10M

Market Snapshot

About

Roivant Sciences is a biopharmaceutical company focused on applying technology and data science to drug development. The company builds subsidiary biotech and healthcare technology companies (Vants) to develop and commercialize medicines and technologies. Roivant aims to improve the efficiency and success rate of bringing innovative therapies to patients through its unique organizational model.